Release Details

TARRYTOWN, N.Y.--(BUSINESS WIRE)--Nov. 10, 2008--Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast its presentation at the Credit Suisse 2008 Healthcare Conference on Wednesday, November 12, 2008. The presentation will provide an overview of the Company and its clinical and research programs and is scheduled to be broadcast live on Wednesday, November 12 at 10:00 a.m. Eastern Time. The session may be accessed through the Company's web site (www.regeneron.com on the Investor Relations page, under the Presentations heading) at the time of the presentation. An archived version of the presentation will be available after the live webcast through December 12, 2008. Additional information about Regeneron and recent news releases are available on the Regeneron worldwide web site at www.regeneron.com

Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions. In addition to ARCALYST^® (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases and has preclinical programs in other diseases and disorders.

    CONTACT: For Regeneron Pharmaceuticals, Inc.
             Investor Relations
             914-345-7640
             invest@regeneron.com
             or
             Laura Lindsay, 914-345-7800
             laura.lindsay@regeneron.com
             or
             Kelly Hershkowitz, 212-845-5624
             khershkowitz@biosector2.com

    SOURCE: Regeneron Pharmaceuticals, Inc.